17
Dec

Thanks to global downsizing, the rapid rise of CROs and mounting pricing pressures, the R&D spends of the world’s biggest drug developers remained flat last year, according to a report.

…read more

Source: Biopharma’s R&D budgets stay about flat amid global cuts

    

0 No comments